echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Professor Zhou Jianfeng: Current status, challenges and prospects of CAR-T cell therapy for hematological tumors The 16th National Leukemia and Lymphoma Academic Conference

    Professor Zhou Jianfeng: Current status, challenges and prospects of CAR-T cell therapy for hematological tumors The 16th National Leukemia and Lymphoma Academic Conference

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Sponsored by the Chinese Medical Association, Hematology Branch of Chinese Medical Association, Leukemia and Lymphoma Group of Hematology Branch of Chinese Medical Association, Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), First Affiliated Hospital of University of Science and Technology of China The 16th National Leukemia and Lymphoma Academic Conference hosted by the Chinese Medical Association will be held in Hefei, Anhui Province on October 8-10, 2021
    .

    At this conference, Professor Zhou Jianfeng from Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology gave a theme report on "Current Status, Challenges and Prospects of CAR-T Treatment of Tumors".
    Yimaitong organized the main contents as follows
    .

    CAR-T cell therapy has gradually become the cornerstone therapy for hematological tumors.
    Professor Zhou said that with the gradual rise of CAR-T cell technology, CAR-T cell therapy is gradually becoming the cornerstone therapy for hematological tumors.
    Single-dose, one-time treatment It brings new hope of cure to patients, and is a "savior" for patients without medicine.
    It can also bring patients better survival and quality of life expectations for more front-line treatment, and changes the concept of clinical treatment of hematological tumors.
    And pattern
    .

    It is worth noting that the ZUMA series of clinical studies have promoted the process of CAR-T cells becoming the cornerstone therapy for lymphoma.
    CAR-T cell monotherapy has changed the current situation of no medicines available for relapsed and refractory patients.
    With the emergence of more new drugs, The ZUMA study is also exploring the efficacy of more combination treatment options.
    The results of multiple studies have also shown that combined treatment can increase the cure rate of lymphoma
    .

    So, can CAR-T cell therapy be applied in the first line? Professor Zhou said that the ZUMA series of studies are also exploring the advancement of CAR-T cell therapy.
    The results of the ZUMA-12 study suggest that the earlier application of CAR-T can benefit patients more
    .

    Professor Zhou believes that CAR-T cells are expected to enter the first-line treatment of lymphoma in the future
    .

    Later, Professor Zhou introduced that CAR-T cell therapy for multiple myeloma (MM) has also explored the possibility of disease cure.
    The results of the CARTITUDE1-5 series are expected to completely change the current MM treatment pattern
    .

    In addition, the results of a single-center, open, single-arm clinical study on the safety and effectiveness of fully humanized targeting BCMA CAR-T cells (CT103A) in the treatment of patients with relapsed and refractory MM initiated by Professor Zhou’s team have been published on Blood Announced, CT103A may provide a new treatment option for patients with relapsed and refractory MM in the future
    .

    Universal CAR-T cells move towards clinical T cells Professor Zhou next introduced several universal CAR-T cell therapies under development: ALLO-501 is an allogeneic CAR-T cell therapy targeting CD19, which is used in the treatment of difficult relapses.
    In clinical studies of therapeutic large B-cell lymphoma (LBCL), it has shown similar efficacy and safety to autologous CAR-T; CTX110 is a kind of T cells from healthy donors edited by CRISPR/Cas9 technology.
    Cell therapy prepared as CAR-T, after normal pretreatment, the efficacy at low doses is average, but the kinetic characteristics are good; GC027 is a ready-to-use CAR-T cell that uses T cells from healthy donors that do not require HLA matching Therapies can target tumor cells expressing CD7 antigen for the treatment of T-cell malignancies.
    The research results show that there are more patients with minimal residual disease (MRD) negative complete remission (CR), and the dynamics expansion is good
    .

    According to Professor Zhou of NK Cell, as of August 2021, 28 CAR-NK clinical trials are in progress, of which 18 are studies on hematological tumors and 10 are studies on solid tumors
    .

    A study by MD Anderson Cancer Center evaluated the efficacy of CAR-NK in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), with a median follow-up of 13.
    8 months, and 8 patients (73%) were objective Remission, 7 patients reached CR
    .

    In recent years, "spot" CAR-NK cells derived from iPSC (induced pluripotent stem cell) have received widespread attention.
    It aims to realize the industrialization of universal CAR-NK cell therapy, solve the problem of the source of NK cells, and avoid peripheral blood NK cells Insufficient numbers and ethical risks of cord blood NK cells, its related products FT516 and FT596 have good initial efficacy in the treatment of patients with relapsed and refractory B-cell lymphoma, and the overall safety is tolerable
    .

    However, Professor Zhou said that many key bottlenecks have not been broken, and further research and exploration are needed
    .

    Combination of CAR-T cells and other advanced drug technologies.
    CAR-T cells can also be used in combination with other advanced drugs, such as the combination with immune checkpoint inhibitors, the combination with oncolytic viruses, and the combination with mRNA technology.
    Breakthrough new developments
    .

    In conclusion, Professor Zhou concluded that CAR-T cell therapy has brought new hope for patients to cure and is changing the pattern of hematological tumor treatment.
    In addition, local companies have good development potential in CAR-T R&D and research.
    On the basis of ensuring better efficacy and safety, local companies may have obvious cost advantages and have very good development potential
    .

    Professor Zhou Jianfeng, Chief Physician, and Doctoral Supervisor, Director of the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Deputy Director of the Department of Internal Medicine, Director of the Hubei Blood Immune Cell Therapy Clinical Research Center, Director of the Clinical Research Center of Tongji Hospital, Huazhong Scholars Leading Talent Distinguished Professor Recipient of the National Outstanding Youth Fund, Member of the Standing Committee of the Hematology Branch of the Chinese Medical Association, Vice Chairman of the Hematology Branch of the Chinese Anti-Cancer Association, Deputy Chairman of the Hematology Oncology Committee of the Chinese Association of Chinese and Western Medicine, Vice Chairman of the Chinese Anti-Leukemia Alliance, Deputy of the Translational Medicine Group of the Oncology Branch of the Chinese Medical Association Team leader Chinese Journal of Hematology and other academic journals and other academic journals and other academic journals and other major clinical professional directions are molecular diagnosis of leukemia, lymphoma and other hematological tumors, molecular and cellular immunotherapy
    .

    More than 100 professional papers have been published in international journals such as Nature Genetics, J Exp Med, Cell Research, Blood, JACI, JNCI, and leukemia
    .

    Poke "read the original text", we make progress together
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.